{"id":"NCT01469182","sponsor":"ALK-Abell√≥ A/S","briefTitle":"A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)","officialTitle":"A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2011-11-10","resultsPosted":"2014-06-05","lastUpdate":"2017-03-03"},"enrollment":914,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Allergy"],"interventions":[{"type":"BIOLOGICAL","name":"SCH 39641","otherNames":["MK-3641"]},{"type":"DRUG","name":"Placebo for SCH 39641","otherNames":[]}],"arms":[{"label":"SCH 39641 12 Amb a 1-U","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study assessed the safety profile of short ragweed (Ambrosia artemisiifolia) in participants with ragweed-induced rhinoconjunctivitis with or without asthma. The primary objective was to compare treatment-emergent adverse events (AEs) for participants treated with short ragweed allergy immunotherapy tablet (AIT) with those treated with placebo.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (AEs)","timeFrame":"Up to Day 35","effectByArm":[{"arm":"SCH 39641 12 Amb a 1-U","deltaMin":321,"sd":null},{"arm":"Placebo","deltaMin":130,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24836393"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":609},"commonTop":["Throat irritation","Paraesthesia oral","Ear pruritus","Oral pruritus","Headache"]}}